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Abstract
Background—We assessed whether 7 days of zidovudine+lamivudine postpartum with single-
dose nevirapine at labor decreases nevirapine resistance in HIV-infected women in Malawi.
Methods—HIV-infected pregnant women receiving intrapartum single-dose nevirapine and 7
days of zidovudine+lamivudine (n=132), and women receiving intrapartum single-dose nevirapine
alone (n=66) were followed from an antenatal visit through 6 weeks postpartum. Plasma
specimens at 2 and 6 weeks postpartum were tested for genotypic resistance to nevirapine by
population sequencing and sensitive real-time PCR. Poisson regression was used to determine
predictors of postpartum nevirapine resistance.
Results—Median HIV RNA was similar at entry (4.27 log vs. 4.35 log, p=0.87), differed at 2
weeks postpartum (2.67 log vs. 3.58 log, p<0.0001), but not at 6 weeks postpartum (4.49 log vs.
4.40 log, p=0.79), between single-dose nevirapine/zidovudine+lamivudine and single-dose
nevirapine groups, respectively. Nevirapine resistance, measured by population sequencing and
sensitive real-time PCR, was significantly less common in those receiving single-dose nevirapine/
zidovudine+lamivudine compared to single-dose nevirapine, respectively, at 2 weeks (10% (4/40)
vs. 74% (31/42), p<0.0001) and 6 weeks postpartum [10% (11/115) vs. 64% (41/64), p<0.0001;
adjusted relative risk=0.18, 95% confidence interval (0.10–0.34)].
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Conclusions—The significant decrease in nevirapine resistance conferred by one week of
zidovudine+lamivudine should help policymakers optimize peripartum HIV prophylaxis
recommendations.
INTRODUCTION
Providing a single-dose of nevirapine, a non-nucleoside reverse transcriptase inhibitor
(NNRTI), to HIV-infected women during labor and to their infants within 72 hours of birth
greatly reduces perinatal HIV transmission 1,2. However, nevirapine’s low threshold to
resistance and long half-life allow viruses with NNRTI resistance mutations to emerge 3–5.
Importantly, a single mutation may confer resistance to the two most commonly used
NNRTIs, nevirapine and efavirenz.
A recent meta-analysis found that at 6 to 8 weeks postpartum, nevirapine mutations may
occur in 36% (95% confidence interval (CI) 23–51%) of women who receive single-dose
nevirapine at labor and in 53% (95% CI 38%–67%) of their infants who become HIV-
infected 6. Use of more sensitive assays has demonstrated an even higher proportion of
women with resistant variants, which can persist at very low levels in a small proportion of
women for up to 5 years 5. In the absence of continued use of antiretroviral drugs, these
mutations fade but remain archived in the latent reservoir 7 and may increase the risk of
failure to respond to subsequent therapy 8–13.
Efficacious, simple, cost-effective strategies to decrease the selection of nevirapine resistant
variants are needed. We took advantage of two ongoing projects in Lilongwe, Malawi, to
assess whether adding zidovudine+lamivudine for 7 days to single-dose nevirapine at labor
would decrease postpartum emergence of nevirapine viral resistance in HIV-infected women
and their infants.
METHODS
Women attending antenatal clinics in Lilongwe are tested for HIV infection at their first
antenatal visit through a program to reduce perinatal HIV transmission administered by the
University of North Carolina (UNC Project), together with the Malawi Ministry of Health.
Women found to be HIV-1 infected who have a CD4 cell count ≥ 250 cells/mm3 are offered
single-dose nevirapine14. Women with < 250 cells/mm3 are started on combination
antiretroviral therapy (ART) 15.
The Breastfeeding, Antiretrovirals, Nutrition (BAN) Study (www.thebanstudy.org),
conducted in Lilongwe by UNC Project and sponsored by the U.S. Centers for Disease
Control and Prevention (CDC), is a randomized clinical trial to assess the benefit and safety
of antiretroviral medications given to infants or their mothers during breastfeeding
(ClinicalTrials.gov Identifier: NCT00164736) 16. From April, 2004 to September, 2008,
HIV-1 infected women who met eligibility criteria were offered participation in the BAN
study as an alternative to the standard regimen. All women and infants in the BAN study
received single-dose nevirapine at labor and an additional 7 days of twice daily zidovudine
+lamivudine. Mother-infant pairs were randomized to receive 28 weeks of maternal or infant
daily antiretroviral prophylaxis or no ART during the breastfeeding period.
Women were eligible for the BAN study if they met the following criteria at enrollment:
HIV-1 infected, ≤30 weeks gestation, ≥18 years of age (≥14 years of age if married),
hemoglobin >7 g/dL, CD4 lymphocyte count ≥ 200 cells/mm3 (later raised to 250 cells/
mm3), no prior history of antiretroviral use, normal liver function tests (alanine
Farr et al. Page 2













aminotransferase <2.5 times the upper limit of normal), and no serious complications of
pregnancy.
Based on sample size calculations, we selected 132 BAN study participants for the current
study from women who were randomized to the arm in which neither mother nor child
received antiretrovirals after the 7 days of zidovudine+lamivudine (referred to hereafter as
the nevirapine/zidovudine+lamivudine group). The first 132 consecutive women with
available specimens were included, and women with HIV-infected infants were over-
sampled. The comparison group in the current analysis (the nevirapine group) consisted of
110 consecutively presenting HIV-infected pregnant women receiving single-dose
nevirapine through the UNC Project public program at a Lilongwe clinic not participating in
the BAN study. Eligibility for the nevirapine group was similar to that in the BAN Study in
terms of age, hemoglobin level, CD4 count, history of ARV use and liver function. Study
visits relevant for this analysis occurred approximately one week after the first antenatal
clinic visit, 2 weeks after the first antenatal visit, at delivery, and at 2 and 6 weeks
postpartum. All women gave written informed consent for study participation.
All mothers’ antenatal plasma specimens were tested for HIV viral load, hemoglobin level,
CD4 lymphocyte count, and liver function. Drug concentrations were measured at delivery
to assess compliance with drug regimens. At 2 and 6 weeks postpartum, all plasma and
breastmilk specimens were tested for nevirapine, zidovudine and lamivudine concentrations
and resistance mutations using population sequencing and real time PCR. Mutations were
classified based on information in the Stanford University Drug Resistance Database
(http://hivdb.stanford.edu/index.html). If any resistance mutation was detected postpartum,
an antenatal plasma specimen was tested for preexisting resistance mutations. All plasma
from HIV-infected infants was tested for nevirapine, zidovudine and lamivudine resistance
mutations using population sequencing and real time PCR.
All blood plasma specimens collected at 2 and 6 weeks postpartum were evaluated for drug
resistance mutations through population sequencing and real-time PCR, regardless of viral
load level. Population sequencing cannot generally detect mutant virus at levels lower than
20%, while real-time PCR can detect mutant virus at levels as low as 0.5 to 1.0%17. HIV-1
RNA was quantified from blood plasma using the Roche Amplicor Monitor v1.5 kit
(Pleasanton, CA; LLQ = 400 copies/mL). HIV-1 RNA was quantified from 0.6 mL whole
breastmilk pre-treated with 209ul Abbott RNA sample prep lysis buffer and 60ul Abbott
Proteinase K (53°C incubation for 20 min) using the Abbott RealTime HIV-1 assay (Abbott
Molecular, Des Plaines, IL; LLQ = 40 copies/ml). For population sequencing, the reverse
transcriptase gene was amplified using an in-house RT-PCR assay from plasma or
breastmilk viral RNA derived from Roche or Abbott RNA isolation, or after extraction using
the QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA). Primers for cDNA synthesis and
nested PCR were designed from the subtype C consensus (http://www.hiv.lanl.gov) and the
final PCR product corresponded to HXB2 nt 2564–3682. PCR products were sequenced
using the ABI PRISM BigDye v1.1 Terminator Cycle Sequencing kit. Each product was
sequenced with the second round PCR primers and two internal primers (5’-
ATATATGGATGACTTGTATG-3’ and 5’-TTGTCTGGTGTGGTAAATCC-3’). After
alignment using Sequencher 4.5, resistance mutations were determined as described above.
A few blood plasma RNAs were sequenced using TruGene HIV-1 Genotyping Kit (Siemens
Healthcare Diagnostics, Tarrytown, NY). Sample integrity was checked by aligning the
sequences using CLC Sequence Viewer (CLC bio A/S) and Treemaker
(http://www.hiv.lanl.gov/content/sequence/TREEMAKER/TreeMaker.html).
For the sensitive real-time PCR resistance assays, HIV-1 genomic RNA from the blood
plasma samples was extracted using Qiagen BioRobot M48 from 200 µL patient plasma. A
Farr et al. Page 3













region of the HIV-1 template that included nucleotide 58 to nucleotide 777 of RT was RT-
PCR amplified as previously described 17,18. This RT-PCR-amplified template was used in
the real-time PCR testing for drug resistance mutations. For each mutation, we had
established assay cut-offs (ΔCTs) equivalent to 0.5%–1% mutant virus, which are above the
background reactivity observed when testing wild type virus, pre-nevirapine rollout samples
from South Africa 17. The RNA samples were tested for five mutations: RT K103N,
Y181C, and T215F/Y (ΔCT 10 cycles), V106M and M184V (ΔCT 8.5 cycles). Sensitive
testing for codon 215 Y and F mutations was performed to rule out evidence of primary
resistance because population sequence-detectible polymorphisms were present at that
position. To verify samples positive for drug resistance mutations by real-time PCR, we
analyzed a 575 bp region of RT (nt. 133–708 of RT) amplified from the primary RT-PCR of
the specimen and also the mutation-positive amplicon derived from the real-time PCR test.
All templates underwent double-strand chain-termination sequencing (Big Dye kit v1.1,
Applied Biosystems). The real-time PCR amplicon sequences were evaluated for insertions
and deletions to verify that the virus sequence was intact. We also examined for the presence
of other mutations linked on the mutation-targeted amplicons generated by the real-time
PCRs 18.
Drug concentrations in blood plasma and breastmilk were measured using validated high
performance liquid chromatography (HPLC)/ultraviolet (UV) methods as previously
described 19–21. For blood plasma, the method was validated over the range of 10–10,000
ng/ml for all analytes. Intra- and interday precision was within 5.1% and 5.6%, respectively,
and intra- and interday accuracy (average percent deviation from nominal) was between
97% and 105%. For breastmilk, the method was validated over the range of 20 to 20,000 ng/
mL. Intra- and interday precision was within 3.6% and 7.5%, respectively, and intra- and
interday accuracy was within 99.8% and 98.7%, respectively. Drug exposure was calculated
as area under the concentration-time curve (AUC) from delivery to 6 weeks postpartum
using non-compartmental methods and the linear/log trapezoidal rule in WinNonlin® Pro
version 4.0.1 (Pharsight Corp, Mountain View, CA, USA).
We compared characteristics between treatment groups using Pearson’s chi-square and the
Wilcoxon rank sum tests. Cumulative and type-specific nevirapine mutations assessed
through population-sequencing and real-time PCR testing at 2 and 6 weeks postpartum in
plasma and breastmilk were compared by treatment group. A relative risk and 95%
confidence interval for nevirapine resistance comparing women receiving nevirapine/
zidovudine+lamivudine to women receiving nevirapine alone was estimated in a modified
multivariable Poisson regression model using robust error variances 22. Drug resistance
refers to combined results of population sequencing and/or real-time PCR testing, unless
otherwise stated. Unamplifiable specimens and those with viral load levels too low to detect
minority variants were excluded from analyses (2 weeks postpartum: n=54 in sdNVP/ZDV
+3TC group and n=19 in sdNVP group (p=0.001); 6 weeks postpartum: n=15 in sdNVP/
ZDV+3TC group and n=2 in sdNVP group (p=0.05). Statistical analyses were performed
using SAS version 9.1.
The current study was approved by the Malawi National Health Science Research Council
and the institutional review boards at the University of North Carolina at Chapel Hill and the
U.S. Centers for Disease Control and Prevention (ClinicalTrials.gov Identifier
NCT00164762). The institutions’ human experimentation guidelines were followed.
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Demographic and Obstetric Characteristics
Of the 486 women in the sdNVP+ZDV/3TC arm of the BAN study who had completed 6
weeks postpartum as of July 2007, the first 132 (27%) with available specimens were
included in the analysis. Demographic characteristics, CD4 count, hemoglobin levels, and
obstetric complications did not differ between those included and excluded. Of the 110
women enrolled and eligible for the nevirapine group, 66 (60%) had the necessary
specimens available and were included in analyses. No significant differences in loss to
follow-up rates between BAN women and women in the public PMTCT program were
detected at 2 (p=0.34) or 6 (p=0.50) weeks postpartum.
Maternal age, gestational age at entry, parity, viral load, CD4 count, and hemoglobin did not
differ between groups (Table 1). The median BMI at 2 weeks postpartum was lower (22.7
kg/m2 vs. 24.5 kg/m2, p<0.001) and the prevalence of electricity in the home was higher
(23.8% vs. 3.2%, p<0.001) in the nevirapine/zidovudine+lamivudine group compared to the
nevirapine group, respectively.
Obstetric outcomes did not differ between groups (Table 1). There were no statistically
significant group differences for self-reported nevirapine ingestion, where the women took
nevirapine (data not shown), percent redosed, or time between ingestion and delivery.
Among women taking zidovudine+lamivudine, 89.7% reported taking all doses.
Nevirapine compliance, as measured at delivery by self-report (97% and 100%, p=0.15)
(Table 1), median concentration (1301.6 and 1319.4, p=0.999) and percent of women with
detectable nevirapine concentrations (90% and 93%, p=0.47) (Figure 1) did not differ
between groups.
Maternal drug resistance in plasma
At two weeks postpartum, median viral load (2.7 and 3.6, p<0.0001) and percent of women
with detectable nevirapine levels (47% and 82%, p<0.0001) were lower in the nevirapine/
zidovudine+lamivudine compared to the nevirapine group, respectively, (MFigure 1). No
differences between groups were detected in antenatal or 6 week postpartum viral load or
percent with detectable nevirapine concentrations.
At two weeks postpartum, 10% (4/40) of women in the nevirapine/zidovudine+lamivudine
group and 74% (31/42) of women in the nevirapine group had nevirapine resistance
mutations detected through population sequencing or real-time PCR (p<0.0001) (Figure 2).
At 6 weeks postpartum, 10% (4/40) of women in the nevirapine/zidovudine+lamivudine
group had nevirapine resistance mutations detected through population sequencing or real-
time PCR, compared to 64% (41/64) of women in the nevirapine group (p<0.0001). Two
women in the nevirapine/zidovudine+lamivudine group had nevirapine resistance mutations
detected in their antenatal plasma sample and were excluded from analyses.
In the multivariable model predicting nevirapine viral resistance at 6 weeks postpartum
detected through population sequencing or real-time PCR, the addition of zidovudine
+lamivudine to single-dose nevirapine was associated with significant reductions in the risk
of viral resistance to nevirapine in plasma (RR=0.18 95% CI: 0.10–0.34) (Table 2). A higher
nevirapine AUC was also associated with increased risk of nevirapine resistance, while an
association between BMI and nevirapine resistance was of borderline significance. In a
similar model examining nevirapine resistance at 2 weeks postpartum, only drug regimen
predicted viral resistance to nevirapine (RR=0.14, 95% CI 0.05–0.35) (data not shown).
Relative risk estimates did not differ when specimens that could not be sequenced were
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considered wild type, nor when specimens with viral load levels <2000 cp/ml were
excluded.
The most prevalent nevirapine resistance mutations detected through population sequencing
or real-time PCR in maternal plasma were K103N/S, V106A/M, Y181C/I and Y188C/L/H
(Table 3). At 6 weeks postpartum, 2 women in the nevirapine/zidovudine+lamivudine group
and 1 woman in the nevirapine group (the latter who, to our knowledge, had not received
any lamivudine) had newly-emerged lamivudine mutations (M184V).
Forty women in the nevirapine/zidovudine+lamivudine group and 42 women in the
nevirapine group had testable plasma specimens at both 2 and 6 weeks postpartum.
Comparing the nevirapine/zidovudine+lamivudine group to the nevirapine group,
respectively, 10% and 12% had detectable nevirapine resistance at 2 weeks postpartum only,
12.5% and 7% had nevirapine resistance mutations at 6 weeks postpartum only; and 0% and
70% had nevirapine resistance mutations at both 2 and 6 weeks postpartum.
Maternal drug resistance in breastmilk
Seven women had sufficient viral loads in breastmilk to test for viral resistance to
nevirapine. In the nevirapine/zidovudine+lamivudine group, 0/4 women had nevirapine
resistance mutations in breastmilk. In the nevirapine group, 3/3 women had at least one
nevirapine resistance mutation.
Infant Drug Resistance
Mother to child transmission of HIV at 6 weeks in the 515 infants in the BAN study arm
receiving nevirapine/zidovudine+lamivudine and no further ART [7.1% (95% CI: 5.1–
9.1%)] was approximately half that of the 66 infants in the Lilongwe program who received
nevirapine alone [13.9% (6.5–24.7%)] (p=0.06). Among 14 HIV-infected infants in the
current study, one of six (17%) who received nevirapine/zidovudine+lamivudine and three
of eight (38%) who received nevirapine alone had nevirapine resistance mutations.
The detection of maternal nevirapine resistance mutations in plasma or breastmilk did not
always correspond with detection of nevirapine resistance mutations in the 14 HIV-infected
infants. In 4 infants, nevirapine resistance mutations were detected that were not found in
the mother. In another 4 infants, nevirapine resistance mutations were detected in the
mother, but not in the infant. In the 6 remaining infants, three from each group, no
nevirapine resistance mutations were detected in the mother or infant.
Maternal Drug Concentrations
At delivery and 6 weeks postpartum, the percentages of women with detectable nevirapine
concentration in plasma and breastmilk did not vary by drug regimen, antenatal CD4 count,
or antenatal viral load. However, at 2 weeks postpartum, a lower percentage of women in
the nevirapine/zidovudine+lamivudine group, compared to the nevirapine group,
respectively, had detectable nevirapine in plasma (46.9% and 82.0%, p<0.0001, Figure 1)
and breastmilk (78.9% and 90.5%, p<0.05). Additionally, among women taking nevirapine/
zidovudine+lamivudine, we found no association between zidovudine or lamivudine
concentrations at labor and delivery and nevirapine concentration or emergence of
nevirapine viral resistance mutations at 2 or 6 weeks postpartum.
DISCUSSION
The addition of seven days of postpartum zidovudine+lamivudine after single-dose
nevirapine was independently associated with an over 80% reduction in women’s risk of
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nevirapine resistance mutations at 2 and 6 weeks postpartum. Additionally, the 7-day tail of
zidovudine+lamivudine for mothers and infants was associated with a nearly 50% reduction
in vertical HIV transmission at 6 weeks. The finding on vertical transmission of HIV should
be replicated, since our results did not reach statistical significance, we were unable to
examine separately in utero, intrapartum, and postnatal transmission, and another study
found no decrease in perinatal transmission of HIV with the same drug regimen 23. We also
found that in infants who become HIV-infected, nevirapine resistance mutations occur
independently of their mothers, as has also been shown previously24. In addition, mutations
were more prevalent in maternal plasma than breastmilk, suggesting that breast milk is a
protected reservoir for virus 25,26.
The mechanism by which zidovudine+lamivudine reduces nevirapine viral resistance is
unknown, but may be due to its suppressive effects on viral replication. We found lower
levels of viral load at 2 weeks postpartum among women who took zidovudine+lamivudine,
compared to those who did not. Of interest, we also found lower nevirapine concentrations
at 2 weeks postpartum among women who took zidovudine+lamivudine. No differences
were seen in nevirapine compliance between groups. Zidovudine and lamivudine are not
known to have a pharmacologic effect on nevirapine concentration. Whether the finding of
lower nevirapine concentration among women taking zidovudine+lamivudine may be due to
chance or unknown factors is unclear.
One previous study assessed nevirapine resistance with the addition of 4 and 7 days of
zidovudine+lamivudine to single-dose nevirapine at labor compared to single-dose
nevirapine alone among South African women and their infants with HIV-1 subtype C 23.
By 6 weeks postpartum, nevirapine resistance, assessed through population sequencing, was
reduced from 59% in the single-dose nevirapine arm to 12% and 7% in the 4- and 7-day
zidovudine+lamivudine arms, respectively. Of 11 infants with nevirapine resistance
mutations, seven were from the single-dose nevirapine arm and four were from the 4-day
zidovudine+lamivudine arm 23. However, this study did not use real-time PCR testing and
prevalence of resistance mutations may be underestimated; and no information was provided
on drug concentrations over time, limiting inference into biological mechanism. In addition,
the study excluded women with viral loads <2,000 cp/ml. In the current study, specimens
from all HIV-infected women and infants were tested for drug resistance and five women
with viral load levels <2000 cp/ml at enrollment had detectable drug resistance mutations.
Additionally, of the 148 resistance mutations detected in this study, over 54% were detected
through real-time PCR testing only.
Four additional studies assessed the effect of different postpartum short-course drug
regimens on nevirapine resistance after antepartum short-course zidovudine and single-dose
nevirapine at labor and delivery 27–30. All found a reduction in viral resistance to
nevirapine between 2 and 6 weeks postpartum with postpartum short-course ART. However,
these studies were conducted among women who used antepartum short-course zidovudine,
which may not be available in many African settings, and three were among women with
HIV subtypes different from those in much of sub-Saharan Africa 27,29,30. These factors
limit generalizability to HIV-infected women in the least developed countries of sub-
Saharan Africa. The current analysis is among women with HIV-1 subtype C, which has
been reported to have a greater propensity for selecting nevirapine resistance mutations than
other subtypes 3.
The current study is not a randomized clinical trial and some differences between study
groups existed. However, no measured variables substantially confounded the strong
association between drug regimen and nevirapine resistance.
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Several studies show that use of single-dose nevirapine increases the risk of virologic failure
in women and infants when nevirapine-based ART is begun within 6 to 24 months of
receiving single-dose nevirapine 8,9,11,13,31. However, this report shows that the addition
of 7-days of zidovudine+lamivudine postpartum to single-dose nevirapine at labor and
delivery significantly decreased emergence of viral resistance to nevirapine and may have
implications for the success of future NNRTI-based ART. Use of this short-course therapy
should be considered in areas where longer, more intense antenatal antiretroviral
prophylaxis is not feasible.
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Figure 1. Median viral load† and percent of women with detectable nevirapine‡ (NVP) by drug
regimen among HIV-infected mothers*, Lilongwe, Malawi
*Among women with testable plasma specimens at 2 weeks (sdNVP: n=45; sdNVP/ZDV
+3TC: n=53) and 6 weeks postpartum (sdNVP: n=65; sdNVP/ZDV+3TC: n=120);
†Chi square p-value for viral load: antenatal: p=0.87; 2 weeks postpartum: p<0.0001, 6
weeks postpartum: p=0.79
‡Chi square p-value for NVP concentration: delivery: p=0.47; 2 weeks postpartum:
p<0.0001; 6 weeks postpartum: p=0.79
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Figure 2. Prevalence of NVP resistance mutations by drug regimen among HIV-infected
mothers*, Lilongwe, Malawi
*Among women with testable plasma specimens at 2 weeks (sdNVP: n=45; sdNVP/ZDV
+3TC: n=53) and 6 weeks postpartum (sdNVP: n=65; sdNVP/ZDV+3TC: n=120) and no
NVP resistance at an antenatal visit
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Table 2
Predictors of HIV resistance* to nevirapine in plasma among HIV-infected mothers at 6 weeks’ postpartum





0.15 (0.08 – 0.27) 0.18 (0.10 – 0.34)
Single-dose nevirapine 1.0 1.0
Age 0.98 (0.93 – 1.02) †
Log10 (Antenatal Viral
load)
0.80 (0.56 – 1.15) †
Antenatal CD4 count 0.999 (0.998 – 1.000) †
Antenatal hemoglobin 0.89 (0.72 – 1.09) †
Nevirapine concentration at
delivery
1.000 (1.000 – 1.001) †
Nevirapine concentration at
2 weeks postpartum
1.005 (1.002 – 1.007) †
Nevirapine concentration at
6 weeks postpartum
1.002 (1.002 – 1.003) †
Log (Nevirapine Area
Under the Curve)
1.48 (1.11 – 1.97) 1.47 (1.16–1.87)
BMI (kg/m2) at 2 weeks
postpartum
1.17 (1.11 – 1.23) 1.06 (1.00 – 1.13)
RR=Relative risk; CI=confidence interval
*
Detected through population-sequencing or real-time PCR
†
Not included in multivariable model
¶
Includes 153 women with no missing data; 98 in the nevirapine/zidovudine+lamivudine group and 55 in the nevirapine group
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